Obesity, Type 2 Diabetes and Bone in Adults

Jennifer S Walsh, Tatiane Vilaca, Jennifer S Walsh, Tatiane Vilaca

Abstract

In an increasingly obese and ageing population, type 2 diabetes (T2DM) and osteoporotic fracture are major public health concerns. Understanding how obesity and type 2 diabetes modulate fracture risk is important to identify and treat people at risk of fracture. Additionally, the study of the mechanisms of action of obesity and T2DM on bone has already offered insights that may be applicable to osteoporosis in the general population. Most available evidence indicates lower risk of proximal femur and vertebral fracture in obese adults. However the risk of some fractures (proximal humerus, femur and ankle) is higher, and a significant number fractures occur in obese people. BMI is positively associated with BMD and the mechanisms of this association in vivo may include increased loading, adipokines such as leptin, and higher aromatase activity. However, some fat depots could have negative effects on bone; cytokines from visceral fat are pro-resorptive and high intramuscular fat content is associated with poorer muscle function, attenuating loading effects and increasing falls risk. T2DM is also associated with higher bone mineral density (BMD), but increased overall and hip fracture risk. There are some similarities between bone in obesity and T2DM, but T2DM seems to have additional harmful effects and emerging evidence suggests that glycation of collagen may be an important factor. Higher BMD but higher fracture risk presents challenges in fracture prediction in obesity and T2DM. Dual energy X-ray absorptiometry underestimates risk, standard clinical risk factors may not capture all relevant information, and risk is under-recognised by clinicians. However, the limited available evidence suggests that osteoporosis treatment does reduce fracture risk in obesity and T2DM with generally similar efficacy to other patients.

Keywords: Bone; Diabetes; Fat; Fracture; Obesity.

Figures

Fig. 1
Fig. 1
Fat depot actions on bone in obesity

References

    1. ButlandJebb BS, Kopelman P, McPherson K, Thomas S, Mardell J, Parry V. Tackling obesities: future choices—Project Report. London: Government Office for Science; 2007.
    1. . Accessed Nov 2016
    1. De LC, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P, Eisman JA, Kroger H, Fujiwara S, Garnero P, McCloskey EV, Mellstrom D, Melton LJ, III, Meunier PJ, Pols HA, Reeve J, Silman A, Tenenhouse A. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005;16(11):1330–1338. doi: 10.1007/s00198-005-1863-y.
    1. Compston JE, Watts NB, Chapurlat R, Cooper C, Boonen S, Greenspan S, Pfeilschifter J, Silverman S, Diez-Perez A, Lindsay R, Saag KG, Netelenbos JC, Gehlbach S, Hooven FH, Flahive J, Adachi JD, Rossini M, LaCroix AZ, Roux C, Sambrook PN, Siris ES. Obesity is not protective against fracture in postmenopausal women: GLOW. Am J Med. 2011;124(11):1043–1050. doi: 10.1016/j.amjmed.2011.06.013.
    1. Prieto-Alhambra D, Premaor MO, Fina Aviles F, Hermosilla E, Martinez-Laguna D, Carbonell-Abella C, Nogues X, Compston JE, Diez-Perez A. The association between fracture and obesity is site-dependent: a population-based study in postmenopausal women. J Bone Miner Res. 2012;27(2):294–300. doi: 10.1002/jbmr.1466.
    1. Premaor MO, Comim FV, Compston JE. Obesity and fractures. Arq Bras Endocrinol Metabol. 2014;58(5):470–477. doi: 10.1590/0004-2730000003274.
    1. Yang S, Shen X. Association and relative importance of multiple obesity measures with bone mineral density: the National Health and Nutrition Examination Survey 2005–2006. Arch Osteoporos. 2015;10:14. doi: 10.1007/s11657-015-0219-2.
    1. Knapp KM, Welsman JR, Hopkins SJ, Fogelman I, Blake GM. Obesity increases precision errors in dual-energy X-ray absorptiometry measurements. J Clin Densitom. 2012;15(3):315–319. doi: 10.1016/j.jocd.2012.01.002.
    1. Berg RM, Wallaschofski H, Nauck M, Rettig R, Markus MR, Laqua R, Friedrich N, Hannemann A. Positive association between adipose tissue and bone stiffness. Calcif Tissue Int. 2015;97(1):40–49. doi: 10.1007/s00223-015-0008-3.
    1. Evans AL, Paggiosi MA, Eastell R, Walsh JS. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Miner Res. 2015;30(5):920–928. doi: 10.1002/jbmr.2407.
    1. Sornay-Rendu E, Boutroy S, Vilayphiou N, Claustrat B, Chapurlat RD. In obese postmenopausal women, bone microarchitecture and strength are not commensurate to greater body weight: the Os des Femmes de Lyon (OFELY) study. J Bone Miner Res. 2013;28(7):1679–1687. doi: 10.1002/jbmr.1880.
    1. Bachmann KN, Fazeli PK, Lawson EA, Russell BM, Riccio AD, Meenaghan E, Gerweck AV, Eddy K, Holmes T, Goldstein M, Weigel T, Ebrahimi S, Mickley D, Gleysteen S, Bredella MA, Klibanski A, Miller KK. Comparison of hip geometry, strength, and estimated fracture risk in women with anorexia nervosa and overweight/obese women. J Clin Endocrinol Metab. 2014;99(12):4664–4673. doi: 10.1210/jc.2014-2104.
    1. Shen J, Nielson CM, Marshall LM, Lee DC, Keaveny TM, Orwoll ES, Osteoporotic Fractures in Men Mr OSRG The association between BMI and QCT-derived proximal hip structure and strength in older men: a cross-sectional study. J Bone Miner Res. 2015;30(7):1301–1308. doi: 10.1002/jbmr.2450.
    1. Majumder S, Roychowdhury A, Pal S. Effects of trochanteric soft tissue thickness and hip impact velocity on hip fracture in sideways fall through 3D finite element simulations. J Biomech. 2008;41(13):2834–2842. doi: 10.1016/j.jbiomech.2008.07.001.
    1. Lang T, Cauley JA, Tylavsky F, Bauer D, Cummings S, Harris TB, Health ABCS Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res. 2010;25(3):513–519. doi: 10.1359/jbmr.090807.
    1. Scott D, Daly RM, Sanders KM, Ebeling PR. Fall and fracture risk in sarcopenia and dynapenia with and without obesity: the role of lifestyle interventions. Curr Osteoporos Rep. 2015;13(4):235–244. doi: 10.1007/s11914-015-0274-z.
    1. Himes CL, Reynolds SL. Effect of obesity on falls, injury, and disability. J Am Geriatr Soc. 2012;60(1):124–129. doi: 10.1111/j.1532-5415.2011.03767.x.
    1. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res. 2000;15(8):1526–1536. doi: 10.1359/jbmr.2000.15.8.1526.
    1. Reid IR, Ames RW, Evans MC, Sharpe SJ, Gamble GD. Determinants of the rate of bone loss in normal postmenopausal women. J Clin Endocrinol Metab. 1994;79(4):950–954.
    1. Cornish J, Callon KE, Bava U, Lin C, Naot D, Hill BL, Grey AB, Broom N, Myers DE, Nicholson GC, Reid IR. Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol. 2002;175(2):405–415. doi: 10.1677/joe.0.1750405.
    1. Hamrick MW, Ferrari SL. Leptin and the sympathetic connection of fat to bone. Osteoporos Int. 2008;19(7):905–912. doi: 10.1007/s00198-007-0487-9.
    1. Reid IR. Fat and bone. Arch Biochem Biophys. 2010;503(1):20–27. doi: 10.1016/j.abb.2010.06.027.
    1. Lenchik L, Register TC, Hsu FC, Lohman K, Nicklas BJ, Freedman BI, Langefeld CD, Carr JJ, Bowden DW. Adiponectin as a novel determinant of bone mineral density and visceral fat. Bone. 2003;33(4):646–651. doi: 10.1016/S8756-3282(03)00237-0.
    1. Luo XH, Guo LJ, Xie H, Yuan LQ, Wu XP, Zhou HD, Liao EY. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res. 2006;21(10):1648–1656. doi: 10.1359/jbmr.060707.
    1. Kajimura D, Lee HW, Riley KJ, Arteaga-Solis E, Ferron M, Zhou B, Clarke CJ, Hannun YA, DePinho RA, Guo XE, Mann JJ, Karsenty G. Adiponectin regulates bone mass via opposite central and peripheral mechanisms through FoxO1. Cell Metab. 2013;17(6):901–915. doi: 10.1016/j.cmet.2013.04.009.
    1. Riis BJ, Rodbro P, Christiansen C. The role of serum concentrations of sex steroids and bone turnover in the development and occurrence of postmenopausal osteoporosis. Calcif Tissue Int. 1986;38(6):318–322. doi: 10.1007/BF02555743.
    1. Walsh JS, Henriksen DB. Feeding and bone. Arch Biochem Biophys. 2010;503(1):11–19. doi: 10.1016/j.abb.2010.06.020.
    1. Walsh JS, Evans AL, Bowles S, Naylor KE, Jones KS, Schoenmakers I, Jacques RM, Eastell R. Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. Am J Clin Nutr. 2016;103(6):1465–1471. doi: 10.3945/ajcn.115.120139.
    1. Morley JE, Baumgartner RN. Cytokine-related aging process. J Gerontol A Biol Sci Med Sci. 2004;59(9):M924–M929. doi: 10.1093/gerona/59.9.M924.
    1. Cohen A, Dempster DW, Recker RR, Lappe JM, Zhou H, Zwahlen A, Muller R, Zhao B, Guo X, Lang T, Saeed I, Liu XS, Guo XE, Cremers S, Rosen CJ, Stein EM, Nickolas TL, McMahon DJ, Young P, Shane E. Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab. 2013;98(6):2562–2572. doi: 10.1210/jc.2013-1047.
    1. Ng AC, Melton LJ, 3rd, Atkinson EJ, Achenbach SJ, Holets MF, Peterson JM, Khosla S, Drake MT. Relationship of adiposity to bone volumetric density and microstructure in men and women across the adult lifespan. Bone. 2013;55(1):119–125. doi: 10.1016/j.bone.2013.02.006.
    1. Zhang P, Peterson M, Su GL, Wang SC. Visceral adiposity is negatively associated with bone density and muscle attenuation. Am J Clin Nutr. 2015;101(2):337–343. doi: 10.3945/ajcn.113.081778.
    1. Premaor M, Parker RA, Cummings S, Ensrud K, Cauley JA, Lui LY, Hillier T, Compston J, Study of Osteoporotic Fractures Research G Predictive value of FRAX for fracture in obese older women. J Bone Miner Res. 2013;28(1):188–195. doi: 10.1002/jbmr.1729.
    1. Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA, Trial HPF. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. J Clin Endocrinol Metab. 2009;94(9):3215–3225. doi: 10.1210/jc.2008-2765.
    1. McClung MR, Boonen S, Torring O, Roux C, Rizzoli R, Bone HG, Benhamou CL, Lems WF, Minisola S, Halse J, Hoeck HC, Eastell R, Wang A, Siddhanti S, Cummings SR. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211–218. doi: 10.1002/jbmr.536.
    1. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495–505. doi: 10.1093/aje/kwm106.
    1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporosis Int. 2007;18(4):427–444. doi: 10.1007/s00198-006-0253-4.
    1. Shah VN, Shah CS, Snell-Bergeon JK. Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabet Med. 2015;32(9):1134–1142. doi: 10.1111/dme.12734.
    1. Fan Y, Wei F, Lang Y, Liu Y. Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int. 2016;27(1):219–228. doi: 10.1007/s00198-015-3279-7.
    1. Dytfeld J, Michalak M. Type 2 diabetes and risk of low-energy fractures in postmenopausal women: meta-analysis of observational studies. Aging Clin Exp Res. 2016
    1. Hu F, Jiang C, Shen J, Tang P, Wang Y. Preoperative predictors for mortality following hip fracture surgery: a systematic review and meta-analysis. Injury. 2012;43(6):676–685. doi: 10.1016/j.injury.2011.05.017.
    1. Ekstrom W, Al-Ani AN, Saaf M, Cederholm T, Ponzer S, Hedstrom M. Health related quality of life, reoperation rate and function in patients with diabetes mellitus and hip fracture—a 2year follow-up study. Injury. 2013;44(6):769–775. doi: 10.1016/j.injury.2012.10.003.
    1. Zhang W, Shen X, Wan C, Zhao Q, Zhang L, Zhou Q, Deng L. Effects of insulin and insulin-like growth factor 1 on osteoblast proliferation and differentiation: differential signalling via Akt and ERK. Cell Biochem Funct. 2012;30(4):297–302. doi: 10.1002/cbf.2801.
    1. Shanbhogue VV, Hansen S, Frost M, Jorgensen NR, Hermann AP, Henriksen JE, Brixen K. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur J Endocrinol. 2016;174(2):115–124. doi: 10.1530/EJE-15-0860.
    1. Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar S, Link TM. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(11):5045–5055. doi: 10.1210/jc.2010-0226.
    1. Patsch JM, Burghardt AJ, Yap SP, Baum T, Schwartz AV, Joseph GB, Link TM. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J Bone Miner Res. 2013;28(2):313–324. doi: 10.1002/jbmr.1763.
    1. Starup-Linde J, Vestergaard P. Biochemical bone turnover markers in diabetes mellitus—a systematic review. Bone. 2016;82:69–78. doi: 10.1016/j.bone.2015.02.019.
    1. Starup-Linde J, Eriksen SA, Lykkeboe S, Handberg A, Vestergaard P. Biochemical markers of bone turnover in diabetes patients—a meta-analysis, and a methodological study on the effects of glucose on bone markers. Osteoporos Int. 2014;25(6):1697–1708. doi: 10.1007/s00198-014-2676-7.
    1. Leite Duarte ME, da Silva RD. Histomorphometric analysis of the bone tissue in patients with non-insulin-dependent diabetes (DMNID) Rev Hosp Clin Fac Med Sao Paulo. 1996;51(1):7–11.
    1. Manavalan JS, Cremers S, Dempster DW, Zhou H, Dworakowski E, Kode A, Kousteni S, Rubin MR. Circulating osteogenic precursor cells in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012;97(9):3240–3250. doi: 10.1210/jc.2012-1546.
    1. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17(10):1514–1523. doi: 10.1007/s00198-006-0155-5.
    1. Avery NC, Bailey AJ. The effects of the Maillard reaction on the physical properties and cell interactions of collagen. Pathol Biol (Paris) 2006;54(7):387–395. doi: 10.1016/j.patbio.2006.07.005.
    1. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26(1):93–100. doi: 10.1007/s00774-007-0784-6.
    1. Farr JN, Khosla S. Determinants of bone strength and quality in diabetes mellitus in humans. Bone. 2016;82:28–34. doi: 10.1016/j.bone.2015.07.027.
    1. Furst JR, Bandeira LC, Fan WW, Agarwal S, Nishiyama KK, McMahon DJ, Dworakowski E, Jiang H, Silverberg SJ, Rubin MR. Advanced glycation endproducts and bone material strength in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(6):2502–2510. doi: 10.1210/jc.2016-1437.
    1. Tilling LM, Darawil K, Britton M. Falls as a complication of diabetes mellitus in older people. J Diabetes Complicat. 2006;20(3):158–162. doi: 10.1016/j.jdiacomp.2005.06.004.
    1. Hewston P, Deshpande N. Falls and balance impairments in older adults with type 2 diabetes: thinking beyond diabetic peripheral neuropathy. Can J Diabetes. 2016;40(1):6–9. doi: 10.1016/j.jcjd.2015.08.005.
    1. Mattishent K, Loke YK. Meta-analysis: association between hypoglycaemia and serious adverse events in older patients. J Diabetes Complicat. 2016
    1. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR, Study of Osteoporotic Features Research G Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86(1):32–38. doi: 10.1210/jcem.86.1.7139.
    1. Palermo A, D’Onofrio L, Eastell R, Schwartz AV, Pozzilli P, Napoli N. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int. 2015;26(8):2073–2089. doi: 10.1007/s00198-015-3123-0.
    1. Mannucci E, Dicembrini I. Drugs for type 2 diabetes: role in the regulation of bone metabolism. Clin Cases Miner Bone Metab. 2015;12(2):130–134.
    1. Ali AA, Weinstein RS, Stewart SA, Parfitt AM, Manolagas SC, Jilka RL. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology. 2005;146(3):1226–1235. doi: 10.1210/en.2004-0735.
    1. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, Kravitz BG, Yu D, Heise MA, Aftring RP, Viberti G, Diabetes Outcome Progression Trial Study Group Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a diabetes outcome progression trial (ADOPT) Diabetes Care. 2008;31(5):845–851. doi: 10.2337/dc07-2270.
    1. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2016;101(1):157–166. doi: 10.1210/jc.2015-3167.
    1. Taylor SI, Blau JE, Rother KI. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 2015;3(1):8–10. doi: 10.1016/S2213-8587(14)70227-X.
    1. Su B, Sheng H, Zhang M, Bu L, Yang P, Li L, Li F, Sheng C, Han Y, Qu S, Wang J. Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists’ treatment: a meta-analysis of randomized controlled trials. Endocrine. 2015;48(1):107–115. doi: 10.1007/s12020-014-0361-4.
    1. Giangregorio LM, Leslie WD, Lix LM, Johansson H, Oden A, McCloskey E, Kanis JA. FRAX underestimates fracture risk in patients with diabetes. J Bone Miner Res. 2012;27(2):301–308. doi: 10.1002/jbmr.556.
    1. Fraser LA, Papaioannou A, Adachi JD, Ma J, Thabane L. Fractures are increased and bisphosphonate use decreased in individuals with insulin-dependent diabetes: a 10year cohort study. BMC Musculoskelet Disord. 2014;15:201. doi: 10.1186/1471-2474-15-201.
    1. Schwartz A, Vittinghof E, Bauer DC, Cummings SR, Grey A, McClung MR, Napoli N, Reid IR, Schafer AL, Wallace RB, Black DM (2015) Bisphosphonates reduce fracture risk in postmenopausal women with diabetes: Results from FIT and HORIZON trials. Paper presented at the American Society for Bone and Mineral Research
    1. Hamann C, Rauner M, Hohna Y, Bernhardt R, Mettelsiefen J, Goettsch C, Gunther KP, Stolina M, Han CY, Asuncion FJ, Ominsky MS, Hofbauer LC. Sclerostin antibody treatment improves bone mass, bone strength, and bone defect regeneration in rats with type 2 diabetes mellitus. J Bone Miner Res. 2013;28(3):627–638. doi: 10.1002/jbmr.1803.
    1. Hamann C, Picke AK, Campbell GM, Balyura M, Rauner M, Bernhardt R, Huber G, Morlock MM, Gunther KP, Bornstein SR, Gluer CC, Ludwig B, Hofbauer LC. Effects of parathyroid hormone on bone mass, bone strength, and bone regeneration in male rats with type 2 diabetes mellitus. Endocrinology. 2014;155(4):1197–1206. doi: 10.1210/en.2013-1960.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner